Another year has flown by, 2025 is just around the corner! We at GCT reflect on a year of growth, collaboration, innovations and significant achievements which brought us 2024.
We extend our sincere gratitude to our valued clients, partners and colleagues for your unwavering dedication to advancing clinical research and improving global healthcare. Each of us at GCT wishes you a warm holiday season and a prosperous New Year, filled with peace, happiness and progress!
We look forward to a fruitful and rewarding 2025 with you!
From all of us at Global Clinical Trials
But before we look ahead to 2025, let`s take a look at key highlights of 2024 as we continue:
Updating our study portfolio:
GCT is dedicated to advancing medical knowledge and improving patient outcomes globally. We proceed to enhance our clinical experience and achieve significant milestones across different therapeutic areas and geographic regions, making a difference to medical research and bringing new treatments to patients in need.
We are proud that this year we successfully completed enrollment for a Phase IV pediatric respiratory trial, two months ahead of schedule, focusing on a new alcohol-free treatment for sore throats.
GCT has also secured a new contract for an epilepsy study, involving sites in Georgia, India, and Ukraine. This important research will explore primary generalized tonic-clonic seizures.
Additionally, we were awarded a project on acute ischemic stroke treatment which has the potential to bring new treatment options to those affected by this painful disease. More information and countries involved are coming soon.
We can proudly mention that we take part and contribute to clinical trials in rare diseases. GCT has recently completed patient recruitment for a Phase III comparative double-blind study on chronic idiopathic thrombocytopenic purpura (ITP).
These are just a few highlights of our ongoing clinical trials in various indications. We actively manage clinical trials across a wide range of therapeutic areas, such as infectious diseases, oncology, cardiovascular, and others.
Expanding our offices
Besides working hard on all clinical trials, Global Clinical Trials is increasing global footprint to better serve the growing demand for clinical trial support worldwide.
To meet the increasing requests for clinical trials services in India, this year we have relocated to a larger office in Mumbai. Similarly, GCT’s Georgia office has moved to a larger workplace in Tbilisi, strengthening its presence and operational capabilities in this region.
We have also expanded into Western Europe (Netherlands, Belgium, and France), providing local expertise and support for clients pursuing European Medicines Agency (EMA) approval.
Expanding our Business Development team
This year our Business Development team welcomed our new member as BD Director – Michaela Vancova, who has almost 20 years of experience in the pharmaceutical industry. This fall she has already successfully represented GCT in various key industry events!
Attending Pharma and Biotech Conferences & Events
GCT Team has actively participated in many impactful industry events which gave us opportunities to learn a lot, to share our experience and to further develop our competence.
To name just a few, GCT was present at the GAPNET, DIA Europe, Bio Korea, ARVO, ASCP, AES …and many other events where we strengthened existing relationships and forged new connections.
We look forward to further exciting projects and partnerships in 2025!
Happy holidays, see you in 2025!